Marea Therapeutics
San Francisco, California, United StatesFounded 202233+ employeesPrivate
$255.4M raisedSeed· last: series b (Jun 2024)· 2 rounds
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly.
